C

Celea Therapeutics

Clinical-stage biopharma developing deupirfenidone for IPF

Vice President of Regulatory Affairs

Regulatory & Quality (Life Sciences)Confirmed live in the last 24 hours
Full-timeBoston, MA, USA

About the Job

Requirements

  • A bachelor's degree in life sciences or a related scientific discipline is required; an advanced degree is preferred, and equivalent experience is considered.
  • At least 15 years of Regulatory Affairs experience in the biotech or pharmaceutical industry, including at least 7 years of leadership and management experience.
  • Demonstrated expertise leading, designing, writing, and submitting regulatory filings, including successfully steering critical IND, NDA, BLA, and MAA filings through submission, approval, and life-cycle management.
  • A track record of successful global regulatory filings and agency interactions, demonstrated by timely submissions and approvals with the FDA, EMA, and other regulatory authorities.
  • In-depth understanding of drug development, product commercialization, and life-cycle management.
  • Ability to build cross-functional relationships, influence effectively internally and externally, collaborate, and present in public forums and to executive teams.
  • An entrepreneurial mindset and comfort operating in a fast-paced, early-stage environment.
  • Proficiency using AI tools to improve the quality and speed of work.

Responsibilities

  • Lead the Global Regulatory Affairs function and own the formulation of overall regulatory strategy and tactical plans to achieve the company’s regulatory goals across all programs.
  • Oversee regulatory submissions and interactions from pre-IND through NDA/MAA filings, as well as global health-authority filings.
  • Develop productive relationships with the FDA and international health authorities and serve as the company’s primary liaison in agency meetings and negotiations.
  • Provide direct regulatory oversight of preclinical, clinical, and CMC activities; review and endorse key development documents, including target labeling, pivotal protocols and study designs, analytical plans, and risk management plans.
  • Develop regulatory structures, processes, and procedures, including thoughtful use of AI and automation, to scale the function with the company.
  • Partner with clinical, preclinical, CMC, quality, and commercial teams; provide counsel, training, and interpretation of FDA and other regulatory guidelines to company personnel.
  • Ensure ongoing regulatory compliance; be accountable for regulatory inspections and audits; and participate in reviewing labeling and promotional materials.
  • Propose and lead regulatory advisory boards and consultancies with clear objectives, and support business development and due diligence with regulatory expertise.
  • Recruit, mentor, and develop a high-performing and collaborative regulatory team as the company grows.

Desired Qualifications

  • Regulatory experience in pulmonology, respiratory, or fibrotic diseases, and a track record of taking programs through Phase 3 toward registration.
  • An advanced degree (PhD, PharmD, or MS), or RAC certification.
  • Experience building a regulatory function in a small or growing clinical-stage biotech.

About the Company

Celea Therapeutics

Clinical-stage biopharma developing deupirfenidone for IPF

Celea Therapeutics develops and advances treatments for severe respiratory diseases, focusing on late-stage development of deupirfenidone (LYT-100), a deuterated form of pirfenidone. Its lead program targets idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and is prepared for Phase 3 trials. Deupirfenidone aims to slow lung function decline and improve tolerability by changing how the drug is processed in the body, potentially offering advantages over current IPF therapies. The company pursues a Phase 3 head-to-head trial (SURPASS-IPF) against an approved therapy, supported by Orphan Drug Designations and funding from investors, with PureTech Health retaining a meaningful stake.

Company size
11-50
Company stage
Growth Equity (Non-Venture Capital)
Total funding
$180M
Headquarters
Boston, MA
Founded
Not listed

Recently Posted Jobs

Explore more opportunities at Celea Therapeutics

See more jobs